Allurion Technologies, Inc.

Healthcare US ALUR

3.1615USD
0.29(10.16%)

Last update at 2025-05-16T16:58:00Z

Day Range

2.873.27
LowHigh

52 Week Range

0.314.00
LowHigh

Fundamentals

  • Previous Close 2.87
  • Market Cap24.31M
  • Volume447785
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-58.04200M
  • Revenue TTM34.75M
  • Revenue Per Share TTM0.67
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.41

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -80.34300M -37.60100M -12.38600M -0.00517M
Minority interest - - - -
Net income -82.30400M -37.74400M -12.38600M -0.00517M
Selling general administrative 46.02M 15.37M 8.82M -
Selling and marketing expenses 46.86M 50.41M 27.14M -
Gross profit 41.50M 50.73M 29.19M -
Reconciled depreciation 1.91M 2.00M 0.71M -
Ebit -69.77700M -33.17500M -13.05600M -0.21147M
Ebitda -69.03100M -32.28000M -12.34900M -0.00517M
Depreciation and amortization 0.75M 0.90M 0.71M 0.21M
Non operating income net other - - - -
Operating income -79.07800M -32.01000M -12.50100M -0.00517M
Other operating expenses 132.54M 96.22M 50.74M 0.00517M
Interest expense 10.57M 4.43M 3.67M -
Tax provision 0.14M 0.14M 0.00000M -
Interest income - - - -
Net interest income -9.09100M -4.42600M -3.66800M -
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense 0.26M 0.14M 3.11M -0.20630M
Total revenue 53.47M 64.21M 38.24M -
Total operating expenses 120.58M 82.74M 41.69M 0.00517M
Cost of revenue 11.97M 13.48M 9.05M -
Total other income expense net -1.26500M -5.59100M 0.12M 0.00000M
Discontinued operations - - - -
Net income from continuing ops -73.77500M -37.74400M -12.38600M -
Net income applicable to common shares - - - -
Preferred stock and other adjustments - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 71.71M 51.37M 39.35M 0.33M
Intangible assets - - - -
Earning assets - - - -
Other current assets 2.41M 2.49M 1.94M -
Total liab 142.20M 122.81M 73.64M 0.31M
Total stockholder equity -70.48700M -71.43600M -34.28500M 0.02M
Deferred long term liab - - - -
Other current liab 14.59M 15.79M 11.30M 0.14M
Common stock 0.00500M 0.05M 0.05M 0.00216M
Capital stock 0.00500M 58.05M 58.02M -
Retained earnings -212.79900M -132.19200M -94.44800M -0.00517M
Other liab - - - -
Good will - - - -
Other assets - - - -
Cash 38.04M 7.68M 25.84M 0.05M
Cash and equivalents - - - -
Total current liabilities 65.42M 75.87M 31.61M 0.31M
Current deferred revenue - - 0.20M -
Net debt 3.82M 51.85M 0.30M 0.12M
Short term debt 40.46M 54.27M 24.14M 0.17M
Short long term debt 38.64M 53.36M 24.14M -
Short long term debt total 41.86M 59.53M 26.14M 0.17M
Other stockholder equity 143.01M 2.71M 2.14M 0.02M
Property plant equipment - - - -
Total current assets 64.82M 43.38M 37.33M 0.05M
Long term investments - - - -
Net tangible assets - - - -
Short term investments - - - -
Net receivables 18.19M 29.35M 6.83M -
Long term debt - 3.10M 2.00M -
Inventory 6.17M 3.87M 2.71M -
Accounts payable 10.38M 5.81M 1.62M -
Total permanent equity - - - -
Noncontrolling interest in consolidated entity - - - -
Temporary equity redeemable noncontrolling interests - - - -
Accumulated other comprehensive income -0.70000M - - -
Additional paid in capital - - - -
Common stock total equity - - - -
Preferred stock total equity - - - -
Retained earnings total equity - - - -
Treasury stock - - - -
Accumulated amortization - - - -
Non currrent assets other 0.12M 2.71M 0.31M 0.28M
Deferred long term asset charges - - - -
Non current assets total 6.90M 7.99M 2.02M 0.28M
Capital lease obligations 3.21M 3.07M - -
Long term debt total - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments -1.60600M -1.55000M -0.91200M -
Change to liabilities - - - -
Total cashflows from investing activities - - - -
Net borrowings - - - -
Total cash from financing activities 95.99M 30.54M 28.95M 0.05M
Change to operating activities - - - -
Net income -80.60700M -37.74400M -12.38600M -0.00517M
Change in cash 30.40M -17.99400M 13.70M 0.05M
Begin period cash flow 8.02M 26.02M 12.31M -
End period cash flow 38.42M 8.02M 26.02M 0.05M
Total cash from operating activities -63.98200M -46.98100M -14.32900M -0.00003M
Issuance of capital stock - 0.00000M 9.87M -
Depreciation 0.75M 2.00M 0.71M -
Other cashflows from investing activities - - - -
Dividends paid - 0.13M - -
Change to inventory -3.70500M -1.15000M -1.28500M -
Change to account receivables -1.31800M -22.81700M -0.70700M -
Sale purchase of stock - -776.54322M - -
Other cashflows from financing activities 95.92M -0.54800M 9.87M -0.14788M
Change to netincome - - - -
Capital expenditures 1.61M 1.55M 0.91M 0.00000M
Change receivables - - - -
Cash flows other operating - - - -
Exchange rate changes - - - -
Cash and cash equivalents changes - - - -
Change in working capital 0.19M -13.78800M -1.27500M 0.00513M
Stock based compensation 8.36M 0.44M 0.31M -
Other non cash items 7.33M 0.84M -2.35300M 0.00000M
Free cash flow -65.58800M -48.53100M -15.24100M -0.00003M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ALUR
Allurion Technologies, Inc.
0.29 10.16% 3.16 - - 0.70 - 0.98 -2.1477
ABT
Abbott Laboratories
1.36 1.02% 134.71 37.15 23.15 4.67 4.97 4.88 19.38
SYK
Stryker Corporation
1.92 0.49% 394.12 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC
0.05 0.06% 86.16 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp
1.27 1.21% 106.13 68.17 24.57 5.85 4.26 6.46 26.80

Reports Covered

Stock Research & News

Profile

Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.

Allurion Technologies, Inc.

11 Huron Drive, Natick, MA, United States, 01760

Key Executives

Name Title Year Born
Dr. Shantanu K. Gaur M.D. Co-Founder, CEO, President, Principal Financial & Accounting Officer and Director 1986
Dr. Samuel G. Levy Co-Founder 1983
Dr. Ram Chuttani M.D. MD, Chief Medical Officer & Founding Partner 1961
Mr. Ojas A. Buch Chief Operating Officer 1973
Mr. Brendan Michael Gibbons J.D. Chief Legal Officer & Corporate Secretary 1976
Mr. Matt Wright Vice President of People NA
Ms. Joyce Johnson Senior Vice President of Regulatory Affairs & Quality Assurance NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.